MX2022011349A - Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo. - Google Patents
Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo.Info
- Publication number
- MX2022011349A MX2022011349A MX2022011349A MX2022011349A MX2022011349A MX 2022011349 A MX2022011349 A MX 2022011349A MX 2022011349 A MX2022011349 A MX 2022011349A MX 2022011349 A MX2022011349 A MX 2022011349A MX 2022011349 A MX2022011349 A MX 2022011349A
- Authority
- MX
- Mexico
- Prior art keywords
- same
- pharmaceutical composition
- glp
- receptor agonist
- preparing
- Prior art date
Links
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 102000018658 Myotonin-Protein Kinase Human genes 0.000 abstract 1
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
- B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
- B01J23/44—Palladium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un novedoso compuesto útil como agente para el tratamiento o la profilaxis de diversas enfermedades metabólicas tales como obesidad o diabetes e hiperlipidemia, por medio de una excelente actividad agonista de GLP-1 y un excelente perfil de DMPK, a un isómero del mismo o a una sal farmacéuticamente aceptable del mismo, a una composición farmacéutica que comprende el compuesto, y a un método para preparar el compuesto.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200033477 | 2020-03-18 | ||
| PCT/KR2021/003287 WO2021187886A1 (ko) | 2020-03-18 | 2021-03-17 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
| KR1020210034452A KR102563111B1 (ko) | 2020-03-18 | 2021-03-17 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011349A true MX2022011349A (es) | 2022-11-10 |
Family
ID=77771773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011349A MX2022011349A (es) | 2020-03-18 | 2021-03-17 | Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230203021A1 (es) |
| JP (1) | JP2023520181A (es) |
| AU (1) | AU2021237185B2 (es) |
| BR (1) | BR112022018646A2 (es) |
| CA (1) | CA3171173A1 (es) |
| CL (1) | CL2022002466A1 (es) |
| CO (1) | CO2022014271A2 (es) |
| IL (1) | IL296336A (es) |
| JO (1) | JOP20220213A1 (es) |
| MX (1) | MX2022011349A (es) |
| PE (1) | PE20230175A1 (es) |
| TW (1) | TWI825398B (es) |
| WO (1) | WO2021187886A1 (es) |
| ZA (1) | ZA202210199B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI751585B (zh) * | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| US11702404B2 (en) | 2019-10-25 | 2023-07-18 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| JP2023537501A (ja) | 2020-08-06 | 2023-09-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| EP4204415A1 (en) | 2020-08-28 | 2023-07-05 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US11851419B2 (en) | 2020-11-20 | 2023-12-26 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| WO2022202864A1 (ja) | 2021-03-24 | 2022-09-29 | 塩野義製薬株式会社 | 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物 |
| WO2022216094A1 (ko) * | 2021-04-08 | 2022-10-13 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
| CR20230495A (es) | 2021-04-21 | 2023-11-30 | Gilead Sciences Inc | Compuestos moduladores del glp-ir carboxibenzimidazólicos. |
| KR20230173166A (ko) | 2021-05-20 | 2023-12-26 | 일라이 릴리 앤드 캄파니 | 마크로시클릭 글루카곤-유사 펩티드 1 수용체 효능제 |
| CA3231153A1 (en) | 2021-09-08 | 2023-03-16 | Kosuke Takemoto | Medicine for prevention and treatment of diseases linked to anti-obesity activity |
| CN116574092A (zh) * | 2022-05-20 | 2023-08-11 | 成都地奥九泓制药厂 | 苯并咪唑或氮杂苯并咪唑类化合物、其制备方法及其应用 |
| WO2024063140A1 (ja) * | 2022-09-22 | 2024-03-28 | 塩野義製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を有する単環化合物 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| WO2024107781A1 (en) | 2022-11-16 | 2024-05-23 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012013130A (es) * | 2010-05-13 | 2013-04-11 | Amgen Inc | Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10. |
| US8778923B2 (en) * | 2011-12-12 | 2014-07-15 | Receptos, Inc. | GLP-1 receptor modulators |
| KR102314286B1 (ko) * | 2016-12-16 | 2021-10-21 | 화이자 인코포레이티드 | Glp-1 수용체 작용제 및 이의 용도 |
| WO2018183112A1 (en) * | 2017-03-27 | 2018-10-04 | Cardurion Pharmaceuticals, Llc | Heterocyclic compound |
| KR102538572B1 (ko) * | 2018-06-15 | 2023-06-01 | 화이자 인코포레이티드 | Glp-1 수용체 효능제 및 그의 용도 |
| TWI751585B (zh) * | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| US11702404B2 (en) * | 2019-10-25 | 2023-07-18 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| CN114761395A (zh) * | 2019-12-02 | 2022-07-15 | 现代药品株式会社 | Glp-1受体激动剂 |
-
2021
- 2021-03-17 WO PCT/KR2021/003287 patent/WO2021187886A1/ko active Application Filing
- 2021-03-17 CA CA3171173A patent/CA3171173A1/en active Pending
- 2021-03-17 US US17/912,129 patent/US20230203021A1/en active Pending
- 2021-03-17 JO JOP/2022/0213A patent/JOP20220213A1/ar unknown
- 2021-03-17 JP JP2022556239A patent/JP2023520181A/ja active Pending
- 2021-03-17 BR BR112022018646A patent/BR112022018646A2/pt unknown
- 2021-03-17 AU AU2021237185A patent/AU2021237185B2/en active Active
- 2021-03-17 TW TW110109865A patent/TWI825398B/zh active
- 2021-03-17 MX MX2022011349A patent/MX2022011349A/es unknown
- 2021-03-17 IL IL296336A patent/IL296336A/en unknown
- 2021-03-17 PE PE2022001989A patent/PE20230175A1/es unknown
-
2022
- 2022-09-09 CL CL2022002466A patent/CL2022002466A1/es unknown
- 2022-09-14 ZA ZA2022/10199A patent/ZA202210199B/en unknown
- 2022-10-05 CO CONC2022/0014271A patent/CO2022014271A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL296336A (en) | 2022-11-01 |
| AU2021237185A1 (en) | 2022-10-06 |
| AU2021237185B2 (en) | 2023-11-30 |
| PE20230175A1 (es) | 2023-02-01 |
| TWI825398B (zh) | 2023-12-11 |
| CO2022014271A2 (es) | 2022-10-21 |
| JOP20220213A1 (ar) | 2023-01-30 |
| ZA202210199B (en) | 2023-06-28 |
| CA3171173A1 (en) | 2021-09-23 |
| BR112022018646A2 (pt) | 2022-11-08 |
| WO2021187886A1 (ko) | 2021-09-23 |
| US20230203021A1 (en) | 2023-06-29 |
| CL2022002466A1 (es) | 2023-03-03 |
| JP2023520181A (ja) | 2023-05-16 |
| TW202200559A (zh) | 2022-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022011349A (es) | Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo. | |
| MX2023006186A (es) | Derivado de benzimidazol y método de preparación del mismo y uso médico del mismo. | |
| MX2021006908A (es) | Compuesto agonista del receptor thrb y metodo de preparacion y uso del mismo. | |
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| EA202092169A1 (ru) | ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ АМИНОПРОПИОНАТНЫХ СОЕДИНЕНИЙ В ЛЕЧЕНИИ ИНФЕКЦИИ SARS-CoV-2 | |
| SG11201901565VA (en) | Pyrazolopyridine derivative having glp-1 receptor agonist effect | |
| MX2020012967A (es) | Combinacion farmaceutica que contiene activador de glucosacinasa y activador del receptor ppar, composicion, preparacion del compuesto, metodo de preparacion para el mismo y usos del mismo. | |
| MX2009011276A (es) | Inhibidor de dpp-iv que incluye el grupo beta-amino, metodo para la preparacion del mismo y composicion farmaceutica que contiene el mismo para prevenir y tratar una diabetes o una obesidad. | |
| WO2019007696A1 (en) | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | |
| MX2011011028A (es) | Agonista del receptor beta de hormona tiroidea novedoso. | |
| WO2014059232A3 (en) | Substituted spiropiperidinyl compounds useful as gpr120 agonists | |
| WO2009121939A3 (en) | C-aryl glycoside compounds for the treatment of diabetes and obesity | |
| AU2020288567A8 (en) | Pyrrolopyrimidine compound and use thereof | |
| MX2009009445A (es) | Derivados novedosos de benzamida y proceso para la preparacion de los mismos. | |
| TW200716607A (en) | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | |
| MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
| CR20210600A (es) | Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa | |
| MX2023006504A (es) | Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo. | |
| WO2019207257A8 (fr) | Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices | |
| MX2022000945A (es) | Composicion para incrementar la expresion de pgc-1alfa. | |
| MX2021003662A (es) | Derivado de aminonorbornano y metodo de fabricacion del mismo y uso del mismo. | |
| MX2019010108A (es) | Derivados de azetidina. | |
| MX2021009971A (es) | Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos. | |
| MY162554A (en) | Novel benzamide derivatives | |
| NZ766972A (en) | Compounds having s1p5 receptor agonistic activity |